3 research outputs found
Additional file 3: of Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology
Graphs showing the Pearson correlations between the MD, AD, and RD with the %O.D. 4G8, GFAP, IBA1, and MBP. The graph includes data from the WT mice (triangles) and APP/PS1 mice (circles) at 2 months of age (grey), 4 months of age (green), 6 months of age (blue), and 8 months of age (red). (JPG 469 kb
Additional file 1: of Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology
The evolution of the weight of the WT and APP/PS1 mice in the longitudinal study at 2, 4, 6, and 8Â months of age. (TIF 87 kb
Discovery of <i>N</i>‑(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer’s Disease
A mini-HTS
on 4000 compounds selected using 2D fragment-based similarity
and 3D pharmacophoric and shape similarity to known selective tau
aggregate binders identified <i>N</i>-(6-methylpyridin-2-yl)quinolin-2-amine <b>10</b> as a novel potent binder to human AD aggregated tau with
modest selectivity versus aggregated β-amyloid (Aβ). Initial
medicinal chemistry efforts identified key elements for potency and
selectivity, as well as suitable positions for radiofluorination,
leading to a first generation of fluoroalkyl-substituted quinoline
tau binding ligands with suboptimal physicochemical properties. Further
optimization toward a more optimal pharmacokinetic profile led to
the discovery of 1,5-naphthyridine <b>75</b>, a potent and selective
tau aggregate binder with potential as a tau PET tracer